 ALPHARETTA, Ga., Jan. 06, 2021 GLOBE NEWSWIRE -- Clearside Biomedical, Inc. NASDAQ:CLSD, a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that it has entered into a securities purchase agreement with institutional investors and certain existing stockholders, providing for the purchase and sale of 4,209,050 shares of common stock at a price of 2.851 per share, priced at-the-market under Nasdaq rules based on the five-day average closing price of the common stock, in a registered direct offering, resulting in total gross proceeds of approximately 12.0 million, before deducting the placement agents fees and other estimated offering expenses. 